Author:
Ugurel Selma,Pföhler Claudia,Gutzmer Ralf
Publisher
Springer Science and Business Media LLC
Reference17 articles.
1. (2017) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Publish Date: November 27. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf. Zugegriffen: 5. Apr. 2024
2. Numakura, Cancer Biology & Therapy 2024, Vol. 25, No. 1, 2312602, https://doi.org/10.1080/15384047.2024.2312602
3. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Supportive Therapie bei onkologischen PatientInnen – Langversion 1.3, 2020, AWMF Registernummer: 032/054OL. https://www.leitlinienprogrammonkologie.de/leitlinien/supportive-therapie/. Zugegriffen: 5. Apr. 2024
4. Wolf SL, Qin R, Menon SP, Rowland KM Jr, Thomas S, Delaune R, Christian D, Pajon ER Jr, Satele DV, Berenberg JL, Loprinzi CL; North Central Cancer Treatment Group Study N05C5 (2010) Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5. J Clin Oncol 28(35):5182–5187
5. Hofheinz RD, Gencer D, Schulz H, Stahl M, Hegewisch-Becker S, Loeffler LM, Kronawitter U, Bolz G, Potenberg J, Tauchert F, Al-Batran SE, Schneeweiss A (2015) Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group. J Clin Oncol 33(22):2444–2449